SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing significant market attention as community members debate the impact of CEO Jensen Huang's last-minute inclusion in the presidential delegation to China. Discussions are heavily focused on potential export regulation easing, the stock's resilience during broader semiconductor sector volatility, and speculative positioning leading into the upcoming earnings report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending after confirming its pivotal REGAL trial has reached 78 of 80 required events, signaling that final clinical trial data is imminent. The community is actively debating the potential for a significant short squeeze due to high short interest and discussing the long-term potential of the GPS treatment platform for AML patients.

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology Group Ltd (WOK) is experiencing intense volatility and extreme upward price movement, driven by retail traders participating in a speculative 'China penny' momentum theme. The community remains deeply divided, with bulls targeting double-digit gains fueled by short squeezes and micro-float dynamics, while bears warn of a recurring 'retail robbery' cycle characterized by dilution, rapid share consolidation, and aggressive sell-offs.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology remains the center of intense market attention as traders aggressively buy the dip, fueled by the conviction that surging AI-driven memory demand and potential supply constraints from a Samsung labor strike will drive long-term upside. The community is actively debating the sustainability of this rally, with bulls citing a low forward price-to-earnings ratio and institutional accumulation while bears warn of technical overextension and potential cyclical risks.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery ($MERY) is trending as a prominent meme coin on the Cronos chain, driven by its tight correlation with $CRO and community-led narratives surrounding its decentralized structure and secure liquidity. Investors are actively discussing the project's long-term potential, frequently highlighting significant holdings by the crypto.com/us exchange as a key indicator of its stability and growth prospects.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF (DRAM) is surging as investors aggressively capitalize on a multi-year memory chip shortage driven by surging demand for AI infrastructure and HBM. The community remains overwhelmingly bullish, dismissing recent volatility as a buying opportunity while highlighting record-breaking asset inflows and the critical role of the fund's major holdings in the AI supply chain.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is experiencing significant volatility and aggressive short-term trading as investors debate its potential for a recovery or a secondary bankruptcy event following recent restructuring. The community is sharply divided, with bulls pointing to the company's silicon carbide technology and strategic positioning in AI data centers, while bears emphasize the ongoing lack of profitability and the history of shareholder dilution.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors anticipate upcoming earnings, with community sentiment divided between excitement over the company's full-stack infrastructure expansion and concerns regarding potential market volatility. While some focus on long-term value and recent infrastructure milestones, others are actively debating the stock's valuation, insider activity, and its correlation with other data center peers ahead of the print.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense retail activity as traders weigh a parabolic rally against fears of a potential 'blow-off top' in the semiconductor sector. Much of the community conversation is split between aggressive dip-buying and short-sellers betting on a technical mean reversion, with many investors actively debating the sustainability of the current AI-fueled demand cycle.

Enhanced Group, Inc. is an elite sports competition and performance products company committed to providing athletes and consumers with products that support health, performance, and recovery. The company offers a portfolio of products and experiences that combine athletic competition, scientific innovation, and consumer engagement. The company is headquartered in New York, NY.

Enhanced Group Inc. - Ordinary Shares - Class A

Enhanced Group Inc

Enhanced Group Inc is gaining significant traction following its recent NYSE listing as investors and followers track the countdown to its inaugural athletic event in Las Vegas. Community sentiment is largely focused on the company's strategic partnership to broadcast the event via a major streaming platform, viewing the games as a high-profile marketing catalyst to drive user acquisition for their telehealth and performance-science business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Oil prices remained elevated, with Brent crude near $107 a barrel and WTI above $102 a barrel.</li><li>Markets are closely watching Trump’s May 14-15 summit with Chinese President Xi Jinping.</li><li>Traders now await Wednesday’s producer price index report and speeches from Fed officials Susan Collins and Lorie Logan.</li></ul>U.S. stock futures edged mostly higher late Tuesday as hotter inflation data, surging oil prices and rising Treasury yields kept Wall Street on edge ahead of another key inflation report and U.S. President Donald Trump’s summit with Chinese President Xi Jinping.As of 10:55 p.m. ET, Nasdaq 100 futures rose 0.2% while S&amp;P 500 futures gained 0.1%. Dow futures, meanwhile, reversed earlier gains and traded slightly lower.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> was ‘bullish’ amid ‘normal’ message volume, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘bullish’ amid ‘high’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>Stocks were also weighed down by another sharp surge in oil prices after Trump criticized the ceasefire between the U.S. and Iran as “unbelievably weak” and “on massive life support” after rejecting an “unacceptable” counterproposal from Tehran. “I would call it the weakest, right now, after reading that piece of garbage they sent us — I didn’t even finish reading it,” Trump said.Here’s how the major U.S. indexes fared during Tuesday’s session:&nbsp;<div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>0.11%</td><td>49,760.56</td></tr><tr><td>S&amp;P 500</td><td>-0.16%</td><td>7,400.96</td></tr><tr><td>Nasdaq Composite</td><td>-0.71%</td><td>26,088.20</td></tr></tbody></table></figure></div>Brent crude traded near $107 a barrel after rising almost 8% over the past three sessions, while West Texas Intermediate crude hovered near $102.Trump later attempted to calm markets during an interview with&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/FoxNews/status/2054261035519926582">Fox News</a>, saying that oil prices would decline once the war ends.&nbsp; "As soon as this war is over, which will not be long, you're going to see oil prices drop and you're going to see a stock market which is already at the highest point in history, go through the roof.”Markets are also monitoring Trump’s highly anticipated May 14-15 summit with Chinese President Xi Jinping in Beijing, where trade talks are expected to dominate despite the ongoing conflict in Iran. Trump said before departing Washington that trade would be the primary focus of the meeting and said the U.S. had Iran “very much under control.”The summit comes as China remains one of Iran’s largest oil buyers and as global markets continue to grapple with disruptions tied to the Strait of Hormuz blockade. Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-05-12/trump-faces-emboldened-xi-in-china-as-iran-war-clips-us-leverage">reported</a> that Trump is seeking business deals and a possible extension of the trade truce reached with China last fall, while Beijing enters negotiations with stronger leverage tied to its control over critical rare-earth supply chains.Trump called his relationship with Xi “fantastic” and said the two countries were “doing very well.”<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>Nvidia (NVDA): The stock slipped nearly 1% in after-hours trading after Nvidia confirmed that CEO Jensen Huang joined Trump’s China delegation for trade talks with Xi Jinping after reports that he was initially not invited.Sellas Life Sciences&nbsp;(SLS): The stock jumped 16% in extended trading after the company said its late-stage Regal leukemia trial is now just&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-pops-big-after-hours-on-imminent-leukemia-trial-data-readout-optimism/cZXXrpWRe0T">two patient events</a> away from triggering a topline data readout.Wendy’s&nbsp;(WEN): The stock logged its best day in nearly three months on Tuesday after reports said that activist investor Nelson Peltz’s Trian Fund Management is exploring&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wendy-s-stock-gains-premarket-what-s-driving-the-rally/cZXX4pWReLY">financing options</a> for a potential take-private deal.Work Medical Technology Group&nbsp;(WOK): The stock surged another 70% in after-hours trading after the company unveiled an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-wok-stock-skyrocketed-in-just-2-days/cZXLTxmRe05">AI-biotech partnership</a> and expanded its blockchain-based healthcare infrastructure and “BioToken” initiatives.Red Cat Holdings (RCAT): The stock slumped 10% after hours following the drone technology company's announcement of a $200 million underwritten public stock offering priced between $9.4 and $9.9 per share.Robinhood Ventures Fund I&nbsp;(RVI): The stock hit a record high on Tuesday amid Robinhood’s plans for Robinhood Ventures Fund II, which aims to expand retail investor access to private startups, including OpenAI and Stripe.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>The yield on the benchmark 10-year Treasury note remained near the key 4.5% level, while gold traded around $4,720 an ounce after inflation data boosted expectations for tighter monetary policy. Silver traded above $87 an ounce and remained one of the strongest-performing precious metals this month.The Kobeissi Letter&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/KobeissiLetter/status/2054221057167634685">said on X</a> that the “U.S. bond market crisis is intensifying,” noting that the 30-year Treasury yield moved above 5% while the benchmark 10-year yield approached the closely watched 4.5% level that previously triggered Trump’s “90-day tariff pause” earlier this year. They also warned that mortgage rates could climb back above 7% if long-term yields continue rising.Among the key catalysts for Wednesday are April’s producer price index report and speeches from Boston Fed President Susan Collins and Dallas Fed President Lorie Logan. Economists polled by Dow Jones expect headline PPI to rise 0.5% month over month, matching March’s pace, while core PPI is expected to increase 0.3%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump greets Chinese President Xi Jinping ahead of a bilateral meeting at Gimhae Air Base on October 30, 2025 in Busan, South Korea. (Photo by Andrew Harnik/Getty Images)

S&P 500, Nasdaq, Dow Futures Mixed As Markets Digest Trump’s Iran Ceasefire Remarks, Hot Inflation — Why NVDA, WOK, RCAT, SLS, RVI Are In Focus 

Trump attempted to calm investors, saying that oil prices would fall once the war in Iran ends, and added that the stock market would “go through the roof.”

Equity

<ul class="summary-bullets"><li>SELLAS is advancing two key programs in AML.</li><li>For Q1, SLS reported a higher net loss as it prepares for a potential application filing to the U.S. Food and Drug Administration for GPS.&nbsp;</li><li>The data readout from the GPS trial will be triggered by a pre-specified event.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group (SLS) jumped more than 20% in after-hours trading Monday following the company’s announcement that its pivotal late-stage trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) is now just two events away from triggering topline data readout.As of May 11, 2026, 78 deaths had occurred in the study, called REGAL, the company said. The prespecified 80th event will trigger analysis and disclosure of results, the company said. SELLAS remains blinded to the data as the study is being conducted by a contract research organization.In December, the company reported that 72 out of the prespecified 80 patient deaths required to trigger the final analysis had occurred as of Dec. 26, 2025.“...we believe that the upcoming results, triggered by reaching the pre-specified 80th event, will be an important milestone for the Company,” Sellas CEO Angelos Stergiou said.<h2 class="st-heading-2">Pipeline Highlights</h2>SELLAS is advancing two key programs in AML. In addition to the REGAL trial, the company has begun dosing patients in an 80-patient mid-stage trial of its experimental drug SLS009 in newly diagnosed, first-line AML patients, including high-risk subsets. Topline data from this study are expected in the fourth quarter of 2026.Stergiou said that Sellas is “entering an exciting time with multiple, high-value potential catalysts that could transform the AML treatment landscape.”<h2 class="st-heading-2">Financial Results and Guidance</h2>As of March 31, 2026, SELLAS had $107.1 million in cash and cash equivalents. The company has since received an additional $7.5 million from the exercise of warrants in the second quarter, extending its cash runway.The company has also established a new at-the-market (ATM) equity facility that gives it the ability to raise up to $150 million over time, though no shares have been sold under the program to date.For the first quarter ended March 31, 2026, SELLAS reported a net loss of $8.4 million, compared with a net loss of $5.8 million in the year-ago period. The increase was driven primarily by higher research and development spending as the company prepares for a potential application filing to the U.S. Food and Drug Administration for GPS following the REGAL readout.<h2 class="st-heading-2">How Did SLS Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user voiced hopes for further rally.<stembedurl>https://www.stocktwits.com/MoMoney80/message/653149990</stembedurl>Another expressed anticipation for the REGAL trial data, noting that it is “nearly here.”<stembedurl>https://www.stocktwits.com/Leotto/message/653149831</stembedurl>A third user expressed optimism for the data triggering an FDA approval, causing a 10x jump in share price.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/653149438</stembedurl>According to data from Koyfin, the two analysts covering Sellas rate it ‘Buy’ or higher. The 12-month average price target on the stock is $10, representing a potential upside of over 90% from the stock’s closing price on Tuesday.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has more than tripled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-invests-250-million-in-cell-manufacturing-at-giga-berlin/cZXXYivRe0G">Tesla Invests $250M In Cell Manufacturing At Giga Berlin As It Eyes Model Y Production Ramp In H2</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism

Sellas investors are now awaiting data readout from the firm’s late-stage trial of galinpepimut-S or GPS in acute myeloid leukemia. 

<ul class="summary-bullets"><li>Investors are awaiting Sellas’ Phase 3 REGAL trial data evaluating its therapy to treat acute myeloid leukemia.</li><li>Analysts expect Sellas to post a first-quarter loss on Tuesday, though it has beaten Wall Street’s estimates in each of the last seven quarters, according to Koyfin data.</li><li>The company carries a price target of $10, nearly double its current trading levels.</li></ul>Sellas (SLS) shares came back into focus on Monday as the stock’s short interest climbed above 30%, with investors bracing for key updates from its acute myeloid leukemia (AML) trial and eagerly awaiting the company’s first-quarter results.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> were up 1% in pre-market trading.According to Koyfin data, short interest in SLS climbed to 30.7% of the float as of May 11, up sharply from 25.5% at the start of April and 28.4% at the beginning of the year, marking its highest level since at least January 2018. The company has roughly 184.5 million outstanding shares.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://app.koyfin.com/charts/g/eq-glnbjy"><img src="https://news.stocktwits-cdn.com/SLS_jpg_da555221b3.webp" alt="SLS.jpg"></a>Source: Koyfin<h2 class="st-heading-2">SLS AML Study In Focus</h2>All eyes are now on Sellas’ Phase 3 REGAL trial data evaluating its therapy to treat acute myeloid leukemia (AML). AML is a fast-growing blood and bone marrow cancer in which abnormal white blood cells crowd out healthy cells.Sellas is using Galinpepimut-S (GPS) for the treatment of AML patients in remission after relapse, with the study nearing the key threshold of 80 deaths (events) needed to trigger the final overall survival analysis.The company had reported 72 events as of Dec. 26, 2025, and said it will begin data analysis and unblind the study once the 80-event target is reached.<h2 class="st-heading-2">SLS Q1 Results In Sight</h2>Analysts expect Sellas to post a quarterly loss on Tuesday, though it has beaten Wall Street’s estimates in each of the last seven quarters, according to Koyfin data. Sellas is expected to post a first-quarter (Q1) loss of $0.06 per share, slightly wider than the $0.05 loss reported in the previous quarter, while loss before interest and tax is forecast to increase to roughly $9 million from $8.3 million a year earlier.Despite the expected losses, Wall Street remains optimistic on the stock’s long-term potential. Koyfin data shows the company has a price target of $10, nearly double its current trading levels.<h2 class="st-heading-2">What Do Retail Traders Think Of SLS?</h2>Retail sentiment on Stoctwits remained in the ‘bearish’ zone over the past 24 hours, while message volumes increased by nearly 50%.However, chatter was largely bullish, with one user stating that statistically “GPS is getting stronger and stronger.”<stembedurl>https://stocktwits.com/vlucky16/message/652911730</stembedurl>Another user highlighted how “actual evidence” outweighs “noise” around the stock.<stembedurl>https://stocktwits.com/Rittit/message/652903884</stembedurl>SLS shares have surged more than 84% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/alpha-tau-drts-stock-pre-market-surge-brain-cancer-study-results/cZXa5LuReh2">DRTS Stock Surges Pre-Market Even As Retail Traders Debate ‘Too Small’ Brain Cancer Trial Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on August 26, 2025, in New York City. 

SLS Stock’s Short Interest Hits 8-Year High Ahead Of Key Phase 3 Leukemia Data, Q1 Earnings – Here’s What Wall Street Expects

According to Koyfin data, short interest in Sellas climbed to 30.7% of the float as of May 11, marking its highest level since at least January 2018.

<ul class="summary-bullets"><li>Deutsche Bank raised its holdings to 137,646 shares valued at $582,000 in the March quarter.</li><li>Sellas’ largest shareholders include Vanguard Group, BlackRock, and State Street, among others.</li><li>The company recently took part in discussions on the EU Biotech Act related to drug approvals, biotech competitiveness, and patient access.</li></ul>Shares of Sellas Life Sciences, Inc. (SLS) are poised to end the week in the green as investors increased their bets on the cancer-drug developer and tracked big money ahead of earnings and a potential acute myeloid leukemia (AML) trial catalyst.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> ended Thursday over 4% lower at 4.93, but shares are tracking their best week in nearly a month after gaining about 11% so far this week.<h2 class="st-heading-2">Deutsche Bank Boosts SLS Stake By 50%</h2>Fresh filings showed that Deutsche Bank increased its stake in SLS by 50% during the March quarter. The bank added 45,958 shares, bringing its total holdings to 137,646 shares valued at $582,000, according to data from Quiver Quantitative.The filing came alongside several smaller institutional stakes, including a more than 500% increase from Rothschild Investment, though the stake remains comparatively small at 127 shares.The company’s top shareholders include BlackRock, now the largest investor, with 12.1 million shares valued at $51.3 million as of March 31, up from 7.54 million shares valued at $28.4 million at the end of last year, per Fiscal AI data. As of the end of last year, Vanguard Group held 8.5 million shares valued at $35.8 million. Geode Capital Management held shares valued at about $13 million, while State Street held a stake valued at $9.3 million.<h2 class="st-heading-2">SLS Q1 Preview</h2>Wall Street expects another loss-making quarter as Sellas continues investing heavily in clinical development and pipeline expansion. According to Koyfin estimates, analysts expect a loss per share (EPS) of $0.06 for the quarter, compared with a loss of $0.05 in the prior quarter. Earnings before interest and taxes (EBIT) is projected to widen to $9 million from about $8.3 million previously.&nbsp;According to Koyfin data, Sellas carries a 12-month average analyst price target of $10, implying an upside of 103% from current levels. Among the two analysts covering the stock, one rates it “Strong Buy” while the other maintains a “Buy” rating.Shareholders are also weighing Sellas’ proposal to add 20 million shares to its&nbsp;stock-based compensation plan, as the company’s remaining share reserve for future awards fell to 7,991 shares by mid-April.&nbsp;An approval would activate a previously approved grant of 1.1 million restricted stock units to Stergiou. As of April 15, the company reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing 2.6% of total float.&nbsp;<h2 class="st-heading-2">AML Trial Catalyst Remains Key Focus</h2>Investors are focused on Sellas’ Phase 3 Regal study evaluating Galinpepimut-S, or GPS, as a maintenance therapy for AML patients whose disease returned but later went back into remission. The event-driven study is approaching the 80 overall-survival-event threshold required to trigger topline analysis. Sellas previously disclosed that 72 survival events had been recorded as of Dec. 26. Once the threshold is reached, the company plans to proceed with database lock, statistical analysis and unblinding.Earlier this week, Stergiou also said that Sellas participated in discussions with European lawmakers and healthcare experts related to the proposed EU Biotech Act. According to Stergiou, the company shared perspectives on biotech competitiveness, drug approvals, market access and health economics while highlighting how policy decisions could affect the speed at which therapies reach patients.The company’s SLS009 CDK9 inhibitor program is also being evaluated in AML and other blood cancers. Preclinical findings previously showed the treatment triggered programmed cell death in leukemia cells and remained active in AML linked to ASXL1 and TP53 mutations.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_af32e3d0de.webp" alt="sls ss.png" width="970" height="143"><figcaption>SLS sentiment and message volume as of May 8 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Duncan74/message/652564125">said</a>, “Big Pharma won't just pay they will fight each other to overpay. The patent cliff turns SELLAS from a luxury into a necessity.”<stembedurl>https://stocktwits.com/Duncan74/message/652564125</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Johnmtnb2018/message/652588999">said</a>, “Angelos was keeping all the cards close to his chest until he showed it to the European Parliament. Nobody will be able to contain this now. Every Big Pharmaceutical in the world is going to come after the gps cure now !”<stembedurl>https://stocktwits.com/Johnmtnb2018/message/652588999</stembedurl>SLS stock has surged 188% over the past year.&nbsp;Editor's note: This story has been updated to reflect BlackRock's increased stake in SLS as of March 31, 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-amazon-ozempic-glp1-ahead-of-earnings/cZX23LbReQx">HIMS Stock Slides After Amazon Escalates GLP-1 War With Ozempic — AI Healthcare Bets In Focus Ahead Of Earnings&nbsp;</a>

SLS stock has surged 188% over the past year. (Photo credit: Getty Images)

SLS Stock Heads For Weekly Win: Deutsche Bank’s Stake Boost Draws Attention Ahead Of Q1 Earnings

SLS Stock - Wall Street expects another loss-making quarter, with Koyfin estimates projecting EPS loss to widen to $0.06 from $0.05.

Wall Street expects another loss-making quarter, with Koyfin estimates projecting EPS loss to widen to $0.06 from $0.05.

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

SELLAS Life Sciences Group (NASDAQ:SLS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

<ul class="summary-bullets"><li>The CEO called the talks “exceptionally constructive” and said the engagement was a “meaningful recognition” of the company’s work.</li><li>Investor focus remains on the Phase 3 Regal trial evaluating GPS for AML, with 72 survival events recorded toward the 80-event topline trigger.</li><li>Sellas is also seeking shareholder approval to expand its equity incentive plan by 20 million shares.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) rose 2% on Monday after CEO Angelos Stergiou said the company was involved in talks with European lawmakers on biotech policy, even as investor focus stayed on its late-stage acute myeloid leukemia (AML) trial.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> closed above the $5 mark on Monday, returning to the level after a two-week gap.<h2 class="st-heading-2">Sellas Flags EU Biotech Act Talks</h2>Stergiou&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7457100362974670848/">said on LinkedIn</a> that Sellas was invited to the European Parliament to meet members and healthcare experts from the Public Health Committee, where the company was asked to share its thoughts, insights, and recommendations on the EU Biotech Act, drug approval processes, market access, health economics, and the region’s competitiveness.Stergiou called the discussions “exceptionally constructive” and said contributing to the EU Biotech Act dialogue was a “meaningful recognition” of the work being done at Sellas. “We had the opportunity to draw direct relevance from our pipeline, sharing how our innovative approaches to cancer therapies intersect with the need for forward-thinking, supportive legislation,” he said.&nbsp;&nbsp;Stergiou said the talks also focused on how policy decisions could affect the speed at which therapies reach patients.&nbsp;<h2 class="st-heading-2">Sellas AML Trial Nears Topline Readout</h2>The policy talks come as investor attention remains centered on Sellas’ ongoing Phase 3 Regal study evaluating GPS, an immunotherapy targeting the Wilms Tumor-1 antigen, as a maintenance treatment for patients with AML whose disease returned but later entered remission.The event-driven trial is approaching the 80 overall-survival-event threshold required to trigger the topline analysis. The company previously said that 72 events had been recorded as of Dec. 26. Once the threshold is reached, Sellas plans to proceed with database lock, statistical analysis and unblinding of the study.Stergiou has said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than initially expected. He also reiterated recently that his “conviction in the REGAL trial’s prospects and ultimate commercial potential remains as steadfast today as it was day 1.”<h2 class="st-heading-2">Sellas Seeks 20M Share Plan Boost</h2>Separately, Sellas has asked shareholders to approve an expansion of its 2023 Amended and Restated Equity Incentive Plan by&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-no-vote-20m-share-plan-before-aml-results/cZQNDC3ReIp">20 million shares</a>, aiming to replenish its stock-based compensation pool. The company said only 7,991 shares remained available for future awards as of mid-April. The approval would also allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect.As of April 15, Sellas reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing about 2.6% of shares outstanding.Beyond Regal, the company has pointed to 2026 as a key year for its CDK9 inhibitor SLS009, with clinical updates and topline data expected from ongoing Phase 2 studies. Preclinical findings showed that the therapy triggered programmed cell death in leukemia cells and remained active in AML associated with ASXL1 and TP53 mutations.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘neutral’ amid over a 200% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_8a78d55d93.webp" alt="sls ss.png" width="974" height="140"><figcaption>SLS sentiment and message volume as of May 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/G_Trade/message/652199176">noted</a> Stergiou’s LinkedIn post and said, “That is the footprint of a company stepping onto a much bigger stage. Add REGAL in the decisive stretch, SLS009 gaining weight, and the CEO speaking with total conviction, and the picture gets louder every day.”<stembedurl>https://stocktwits.com/G_Trade/message/652199176</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Radders99/message/652215190">said</a>, “Most unusual for a small Biotech company to address the EU Public Health Committee on Policy. Strong signal to institutional investors.”<stembedurl>https://stocktwits.com/Radders99/message/652215190</stembedurl>SLS stock has surged 189% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pltr-q1-revenue-jump-quadrupled-profits-but-valuation-concerns-persist/cZQudVUReJA">PLTR Reports Largest Quarterly Revenue Jump, Quadrupled Profits, But Valuation Concerns Persist&nbsp;</a>

SLS stock has surged 189% over the past year. (Photo credit: Getty Images)

SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals 

Sellas was invited to the European Parliament to discuss the EU Biotech Act, drug approvals, and market access.

<ul class="summary-bullets"><li>Investor focus shifted toward a shareholder vote on a proposal to expand the company’s incentive share pool by 20 million shares.</li><li>CEO Angelos Stergiou urged investors to support the expansion, reiterating confidence in the Phase 3 Regal trial.</li><li>The Regal study had recorded 72 overall-survival events as of Dec. 26, nearing the 80-event threshold required to trigger topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) hovered near the $5 level on Thursday as investor attention shifted from upcoming AML trial results to a shareholder vote on a proposal to add 20 million shares to the company’s incentive plan.SLS stock jumped 6% on Thursday to end at 4.95, climbing close to the $5 threshold last hit more than a month ago.&nbsp;<h2 class="st-heading-2">Sellas Seeks 20M Share Incentive Expansion</h2>Sellas CEO Angelos Stergiou recently urged shareholders to support a proposal to expand the share reserve under the company’s 2023 Amended and Restated Equity Incentive Plan by 20 million shares, saying his conviction in the Phase 3 Regal study evaluating GPS in acute myeloid leukemia (AML) remains unchanged.Sellas previously disclosed that 72 overall-survival events had been recorded as of Dec. 26, moving the study closer to the 80-event threshold required for topline analysis. Stergiou also said that a slower accumulation of survival events in oncology trials can sometimes indicate that patients are living longer than initially expected.The proposed equity plan would replenish the company’s stock-based compensation pool after Sellas said only 7,991 shares remained available for future awards under the existing plan as of mid-April. Approval would also allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect.As of April 15, Sellas reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing about 2.6% of shares outstanding.<h2 class="st-heading-2">Retail Flags Dilution Concerns Near $5</h2>Retail investors on Stocktwits voiced concerns about the timing and scale of the proposed equity plan, particularly as the Regal Phase 3 milestone approaches. Sentiment for SLS slipped to ‘neutral’ from ‘bullish’ levels a week ago amid a 32% rise in 24-hour message volumes.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_a286a7daf7.webp" alt="sls ss.png" width="966" height="146"><figcaption>SLS sentiment and message volume as of May 1 | Source: Stocktwits</figcaption></figure>Some investors&nbsp;<a href="https://stocktwits.com/nashvilleRN/message/651903417">argued</a> that the proposal represented about a 20% dilution, questioning whether such a request should be made before the full Phase 3 data are revealed. Meanwhile, another turned&nbsp;<a href="https://stocktwits.com/Usser888990/message/651903766">bearish</a> at the idea of diluting the stock around the $5 range.&nbsp;In a separate&nbsp;<a href="https://stocktwits.com/FlockOfSeagulls/message/651841400">investor poll</a>, about 70% of respondents indicated they planned to vote against the proposal, compared with 30% supporting it. Another investor&nbsp;<a href="https://stocktwits.com/Bio_Wizard/message/651898473">said</a> that they had already voted against the measure and rotated capital into long-term equities.&nbsp;<h2 class="st-heading-2">AML Pipeline Remains In Focus</h2>Despite the debate regarding share dilution, investors are closely watching the upcoming milestones from the company’s AML programs. The event-driven Phase 3 Regal study is evaluating GPS, which activates immune cells that help destroy leukemia cells in patients whose AML returned but later entered remission after additional therapy.Stergiou also pointed to 2026 as an important year for the company’s CDK9 inhibitor SLS009, with clinical updates and top-line data expected from ongoing Phase 2 studies.Preclinical findings presented ahead of a recent cancer summit showed that the therapy triggered the natural self-destruction process in leukemia cells, reduced survival-support proteins, and remained active in AML linked to ASXL1 and TP53 mutations, which are typically associated with poorer outcomes.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-amazon-drives-auto-revenue-r2-buzz/cZQNMpZReIN">Rivian Stock Slides Overnight: Investors Look Past R2 Buzz To Amazon’s Growing Grip On Auto Revenue&nbsp;</a>

SLS stock jumped 6% on Thursday to end at 4.95. (Photo credit: Getty Images)

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results 

Sellas reported 2.64 million stock options and 2.26 million RSUs outstanding as of April 15, representing an equity overhang of about 2.6% of the total float.

<ul class="summary-bullets"><li>Markets eased from record highs as investors brace for the Fed rate decision and a crucial wave of Big Tech earnings.&nbsp;</li><li>Brent oil prices surged above $110 amid renewed geopolitical tensions in the Middle East.</li><li>Gold slips to a three-week low, signaling mixed safe-haven positioning.</li></ul>U.S. stock futures retreated from record highs early Tuesday as investors tread carefully ahead of big tech earnings and the Fed's rate decision tomorrow. Geopolitical tensions are also weighing on sentiment. Hopes for a swift resolution to the conflict in the Middle East dimmed after President Trump reportedly expressed skepticism over Iran’s latest peace proposal.Brent crude soared above $110, while gold slipped to a three-week low. As of 4:00 a.m. ET on Tuesday: Nasdaq futures declined 0.5%, S&amp;P 500 futures slipped 0.3%, Russell 2000 futures were down 0.1%, while Dow futures were flat.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved back to ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’, as the tech sector heads into a critical earnings stretch.&nbsp;Trending Stocks To WatchPoet Technologies (POET):&nbsp;Shares were down another 9% in early pre-market trade on news that&nbsp;Marvell Technologies (MRVL) canceled a purchase order connected to its Celestial AI unit.&nbsp;Sellas Lifesciences (SLS):&nbsp;A portfolio manager, Commonwealth Equity Services, known for backing several “Magnificent Seven” stocks, increased its stake in the cancer drugmaker ahead of a survival-event trigger in its Phase 3 acute myeloid leukemia (AML) program.Nvidia (NVDA) has solidified its status as the most valuable company in the world after hitting a new 52-week high on AI-driven momentum in Monday’s session.&nbsp;Google (GOOGL) has reportedly joined OpenAI and xAI in signing a deal with the U.S. Department of Defense to allow its AI models to be used for classified military work.&nbsp;Oracle (ORCL)&nbsp;is attracting retail interest, driven by buzz around OpenAI's financial health and Oracle’s role as its primary AI backbone.&nbsp;Bed Bath &amp; Beyond (BBBY)&nbsp;is trending on retail radar after reporting its first quarterly revenue growth in five years.&nbsp;Joby Aviation (JOBY):&nbsp;A successful air-taxi demo and a confirmed target for passenger flights in late 2026 are driving this stock 3% higher in early premarket trading.&nbsp;Dynatrace (DT):&nbsp;Activist investor Starboard Value has reportedly built a significant stake in the AI software maker.&nbsp;Intellia Therapeutics (NTLA) and Rocket Labs (RKLB): Cathie Wood’s ARK Invest sold off a portion of its position in Rocket Labs, while adding on to Intellia Therapeutics.&nbsp;Other tickers trending on Stocktwits&nbsp;at the time of writing included Moolec Science SA (MLEC), Canadian Solar Inc (CSIQ), Vir Biotechnology (VIR), and Nio Inc (NIO).Other Catalysts To WatchOn the economic front, traders will be watching the release of the JOLTS Job Openings and CB Consumer Confidence reports this morning.On earnings radar, watch out for quarterly reports from&nbsp;UPS (UPS), General Motors (GM), Commvault Systems (CVLT), JetBlue (JBLU), Sysco (SYY), Spotify (SPOT), Coca-Cola (KO), T-Mobile (TMUS), Kimberly Clark (KMB), Centene (CNC), and Zimmer Biomet (ZBH), before the bell. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Before Fed Call, Earnings Rush: Why POET, MRVL, NVDA, ORCL, SLS Are In Focus

Data from Stocktwits show mixed positioning, with retail turning bullish on SPY but remaining cautious on QQQ.

<ul class="summary-bullets"><li>Commonwealth Equity Services increased its stake by 32%, adding 9,226 shares worth $162,730.</li><li>CEO Angelos Stergiou reaffirmed confidence in the trial, saying his conviction in its commercial potential remains “as steadfast today as it was day 1.”</li><li>Sellas is also seeking shareholder approval to expand its equity incentive plan by 20 million shares.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) came into focus on early Tuesday after a portfolio manager, known for backing several “Magnificent Seven” stocks, increased its stake in the cancer drugmaker ahead of a survival-event trigger in its Phase 3 acute myeloid leukemia (AML) program.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped over 9% on Monday amid rising hopes around the database-lock milestone for Sellas’ Regal study, which could unlock topline survival data from its lead immunotherapy candidate, GPS.<h2 class="st-heading-2">SLS Draws Fresh Institutional Interest</h2>On Monday, Commonwealth Equity Services increased its stake by 32%, adding 9,226 shares to bring its total holdings to 38,470 shares valued at about $162,730 as of March 31. The boost in stake places Sellas among its other heavyweight healthcare bets, including Eli Lilly, Pfizer, and UnitedHealth.Among its larger portfolio, Sellas sits among its “Magnificent Seven” allocations, including Apple, Nvidia, Microsoft and Amazon.Recently, BlackRock also disclosed ownership of 12.1 million shares, representing 6.8% of Sellas’ shares. Additionally, Dagco raised its position by 78% to 1.03 million shares valued at $4.35 million, making Sellas its second-largest allocation alongside healthcare holdings such as Merck, Thermo Fisher Scientific and Johnson &amp; Johnson.<h2 class="st-heading-2">CEO Reaffirms Confidence In Sellas’ AML Trial</h2>The increase in stake comes after Sellas CEO Angelos Stergiou said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-jumps-overnight-ceo-backs-aml-drug-20m-share-plan/cZBNIW8Re2E">late Sunday</a> that his confidence in the Regal study’s commercial potential remains unchanged despite the trial remaining blinded. “My conviction in the REGAL trial’s prospects and ultimate commercial potential remains as steadfast today as it was day 1,” he said.The ongoing event-driven Phase 3 Regal study is evaluating GPS in patients whose acute myeloid leukemia returned but later entered remission following additional therapy. Final analysis is expected once 80 overall-survival events are recorded, which will trigger database lock, statistical analysis and unblinding. The company previously reported 72 survival events as of Dec. 26, bringing the study closer to the required threshold. Stergiou previously said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than initially expected.Beyond the Regal program, Stergiou also said investors should expect updates and topline data readouts from ongoing Phase 2 studies of the company’s CDK9 inhibitor SLS009 this year.&nbsp;<h2 class="st-heading-2">Sellas Proposes 20M Share Reserve Increase&nbsp;</h2>Alongside pipeline progress, Sellas is seeking shareholder approval to expand its share reserve under its 2023 Amended and Restated Equity Incentive Plan by 20 million shares.The company said that only 7,991 shares are available for future awards under the existing plan as of mid-April. The approval would allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect. If rejected, the award would automatically be canceled, and alternative compensation arrangements may be required.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_656e44509c.webp" alt="sls ss.png" width="968" height="147"><figcaption>SLS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/651586857">said</a>, “Far more important than Blackrock or Vanguard is the fact that private wealth and family offices have been actively buying and hoarding shares. Lot of money in that segment. Careful but patient money.”<stembedurl>https://stocktwits.com/OnTheBalance/message/651586857</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Macme/message/651533145">said</a>, “The CEO must have already discussed this 20 million shares with huge partners. It wil pass. Retail is just making noise. The real players like blackrock will surely approve.”<stembedurl>https://stocktwits.com/Macme/message/651533145</stembedurl>SLS stock has surged nearly 250% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-400m-pay-retail-bullish-ahead-of-earnings/cZB8nCTRe5L">Rivian CEO Got $400M While EV Maker Lost $3.6B Last Year — Retail Is Bullish Anyway As Q1 Earnings Near&nbsp;</a>

SLS stock has surged nearly 250% over the past year. (Photo credit: Getty Images)

SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger 

Commonwealth holds Sellas alongside major healthcare names like Eli Lilly, Pfizer, and UnitedHealth.

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy...

Investors are hyper-focused on the REGAL clinical trial hitting its 80th event, with reports confirming 78 events are in and a final data readout now appearing imminent.

Market participants are discussing the potential for a massive short squeeze as over 57 million shares are currently shorted against a low-float, high-conviction retail base.

Bullish investors view the GPS cancer treatment as a transformative therapy with the potential to generate billions in revenue and trigger a major pharmaceutical buyout.

The community remains highly divided, with intense public spats breaking out between retail shareholders, bearish skeptics, and long-time outspoken influencers.

New 13F filings from major players like Invesco and others are being heavily monitored as evidence of sophisticated institutional accumulation before the upcoming binary catalyst.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

SLSSELLAS Life Sciences Group Inc